

A-Labs Capital IV Corp.

(A Capital Pool Company)

Condensed Interim Financial Statements

(Expressed in Canadian Dollars)

(unaudited)

For the three and nine months ended December 31, 2024, and 2023

Notice to Reader

These unaudited condensed interim financial statements of A-Labs Capital IV Corp. (the “Company”) for the three and nine months ended December 31, 2024, have been prepared by and are the responsibility of management.

In accordance with National Instrument 51-102 released by the Canadian Securities Administrators, the Company discloses that these unaudited condensed interim financial statements have not been reviewed by its auditor.

A-LABS CAPITAL IV CORP.
Condensed Interim Statement of Financial Position
(Expressed in Canadian Dollars)
(Unaudited)

	December 31, 2024	(Audited) March 31, 2024
Assets		
Current		
Cash and cash equivalents (Note 3)	\$ 0	\$ 6
	\$ 0	\$ 6
Liabilities		
Current		
Accounts payable and accrued liabilities	\$ 30,453	\$ 34,530
Note payable (note 6)	15,000	
	45,453	34,530
Shareholders' Equity		
Capital stock (Note 4)	239,118	239,118
Share-based payments reserve	0	29,823
Deficit	(284,571)	(303,465)
	(45,453)	(34,524)
Total Liabilities and Shareholders' Equity	\$ 0	\$ 6

Nature of Operations and Going Concern (Note 1)

Approved by the Board

"(signed) Robert Wilson"
Director

"(signed) Hillar Lilles"
Director

A-LABS CAPITAL IV CORP.**Condensed Interim Statement of Loss and
Comprehensive Loss** (Expressed in Canadian Dollars)
(Unaudited)

	<u>For the Three Month Period Ended December 31</u>		<u>For the Nine Month Period Ended December 31</u>	
	2024	2023	2024	2023
Expenses				
Legal fees	\$ 590	\$5,190	\$ 2,025	\$ 10,790
Audit and accounting fees	-96	3,308	1,376	10,315
Operating expenses	0	(2,153)	7,528	4,357
Net and comprehensive loss for the period	\$ 494	\$ 6,345	\$ 10,929	\$ 25,462
Loss per Share				
Basic and diluted loss for the period	\$ 0.000	\$ 0.003	\$ 0.005	\$ 0.013
Weighted average number of shares outstanding (Note 4)	2,000,000	2,000,000	2,000,000	2,000,000

A-LABS CAPITAL IV CORP.

Condensed Interim Statement of Changes in Shareholders' Equity (Deficiency)

(Expressed in Canadian Dollars)

(Unaudited)

	Number of Shares	Amount	Share-based Payments Reserve	Deficit	Total
Balance, March 31, 2024	4,000,000	\$ 239,118	\$ 29,823	\$ (303,465)	\$ (34,524)
Expiry of employee stock options			(29,823)	29,823	
Net loss for the period	-	-		(10,929)	(10,929)
Balance, December 31, 2024	4,000,000	\$ 239,118	\$ 0	\$ (284,571)	\$ (45,453)
Balance, March 31, 2023	4,000,000	\$ 239,118	\$ 29,823	\$ (259,873)	\$ 9,068
Net loss for the period	-	-	-	(25,462)	(25,462)
Balance, December 31, 2023	4,000,000	\$ 239,118	\$ 29,823	\$ (285,335)	\$ (16,394)

A-LABS CAPITAL IV CORP.**Condensed Interim Statement of Cash Flows for the
Nine-Month Period Ended December 31****(Expressed in Canadian Dollars)(Unaudited)**

	December 31, 2024	December 31, 2023
Cash provided by (used in)		
Operating Activities		
Net loss for the period	\$ (10,929)	\$ (25,462)
Changes in non-cash working capital items:		
Accounts payable and accrued liabilities	(4,077)	4,776
Cash (used in) operating activities	(15,006)	(20,686)
Financing Activities		
Note payable (note 6)	15,000	
Cash Provided by financing activities	15,000	
Net change in cash	(6)	(20,686)
Cash, beginning of period	6	20,692
Cash, end of period	\$ 0	\$ 6

A-Labs Capital IV Corp.
Notes to Condensed Interim Financial Statements
For the three and nine months ended December 31, 2024
(Expressed in Canadian Dollars)
(Unaudited)

1. NATURE OF OPERATIONS

A-Labs Capital IV Corp. (the "Company") was incorporated by a Certificate of Incorporation issued pursuant to the provisions of the Canada Business Corporations Act on November 26, 2018. The registered office is located at 2800 Park Place, 666 Burrard Street, Vancouver, BC, V6C 2Z7.

The Company is classified as a Capital Pool Company ("CPC") as defined in Policy 2.4 of the TSX Venture Exchange (the "Exchange"). The principal business of the Company is to identify and evaluate assets or businesses with a view to potentially acquire them or an interest therein by completing a purchase transaction, by exercising of an option or by any concomitant transaction. The purpose of such an acquisition is to satisfy the related conditions of a Qualifying Transaction (as defined below) under the Exchange rules.

In November 2018, the Company issued 2,000,000 common shares for gross proceeds of \$100,000. On September 30, 2019, the Company completed an Initial Public Offering ("IPO") of 2,000,000 of the Company's common shares at \$0.10 per share for aggregate gross proceeds of \$200,000.

As a CPC, the Company's principal business is the identification and evaluation of assets, properties or businesses with a view to acquisition or participation therein subject, in certain cases, to shareholder approval and acceptance by the Exchange. Where an acquisition or participation is warranted (the "Qualifying Transaction"), additional funding may be required. The ability of the Company to fund its potential future operations and commitments is dependent upon the ability of the Company to obtain additional financing.

During the nine months ended December 31, 2024, the Company incurred a loss in the amount of \$10,929 (2023 - \$25,462) and has a cumulative deficit of \$284,571 (March 31, 2024 - \$303,465). These conditions, along with the other matters described above, cast a material uncertainty on the Company's ability to continue as a going concern. Should the Company be unable to continue as a going concern, the adjustments may be material.

2. BASIS OF PRESENTATION

Statement of Compliance

These unaudited condensed interim financial statements have been prepared in accordance and compliance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB") and interpretations of the International Reporting Interpretations Committee, and IAS 34, Interim Financial Reporting.

These unaudited condensed interim financial statements should be read in conjunction with the Company's annual financial statements for the year ended March 31, 2024. The accounting policies adopted in these condensed interim financial statements are consistent with those disclosed in the Company's audited financial statements for the year ended March 31, 2024.

These condensed interim financial statements were authorized for issuance by the Board of Directors on July 25, 2025.

Basis of Measurement

These condensed interim financial statements are presented in Canadian dollars, which is the Company's functional and presentation currency.

A-Labs Capital IV Corp.
Notes to Condensed Interim Financial Statements
For the three and nine months ended December 31, 2024
(Expressed in Canadian Dollars)
(Unaudited)

3. CASH RESTRICTION

The proceeds raised from the issuance of share capital may only be used to identify and evaluate assets or businesses for future investment, with the exception that not more than \$3,000 per month may be used for general and administrative expenses of the Company. These restrictions may apply until completion of the Qualifying Transaction by the Company as pursuant to the policies of the Exchange.

4. CAPITAL STOCK

Authorized

Unlimited number of common voting shares without nominal or par value.

Issued Common Shares

Issued share capital is as follows:

Shares issued for cash	4,000,000
Balance, March 31, 2024, and December 31, 2024	4,000,000

The 2,000,000 shares issued during the seed financing and the subsequent non-brokered private placement are subject to escrow conditions pursuant to the policies of the TSX-V. These shares are considered contingently issuable under IFRS until the Company completes a Qualifying Transaction and will not be considered outstanding for the purpose of the earnings per share calculation.

Options

The Board of Directors of the Company may from time to time, as its discretion, and in accordance with the Exchange requirements, grant to directors, officers and consultants of the Company, non-transferrable options to purchase Common Shares, provided that the number of Common Shares reserved for issuance will not exceed 10% of the issued and outstanding Common Shares.

The following summarizes the stock option activities under the plan:

	Number	Ave Ex Price
Outstanding and exercisable, March 31, 2024	400,000	\$0.10
Outstanding and exercisable, December 31, 2024	0	-

Loss Per Share

The calculation of basic and diluted loss per share for the three and nine month periods ended December 31, 2024, were based on the loss attributable to common shareholders of \$10,929 (2023 - \$25,462) and the weighted average number of shares outstanding of 2,000,000 (2023 - 2,000,000).

A-Labs Capital IV Corp.
Notes to Condensed Interim Financial Statements
For the three and nine months ended December 31, 2024
(Expressed in Canadian Dollars)
(Unaudited)

5. FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES

Capital Management

The Company's objective when managing capital is to maintain its ability to continue as a going concern until a Qualifying Transaction can be completed. This involves ensuring there are sufficient cash resources to fund the identification and evaluation of potential acquisitions. To secure additional capital necessary to pursue these plans, the Company may attempt to raise additional funds through the issuance of equity or by securing strategic partners.

The Company includes share capital in the definition of capital.

The Company is not subject to externally imposed capital requirements other than the cash restriction disclosed in Note 3.

Risk Disclosures and Fair Values

The Company's financial instruments, consisting of accrued liabilities, approximate fair values due to the relatively short-term maturities of the instruments. It is management's opinion that the Company is not exposed to significant interest, currency or credit risks arising from these financial instruments.

As at December 31, 2024, the Company had current liabilities of \$45,453 and had cash of \$0 to meet its current obligations. As a result, the Company will need to raise additional funds to satisfy its liabilities as they come due.

6. Note Payable

The Company received an amount of \$15,000 from Alterego Ltd., an Israeli incorporated arm's length Company in the form of a note payable. \$10,000 was received from Alterego Ltd. on August 19, 2024, and an additional \$5,000 was received from Alterego Ltd. on August 22, 2024. The note bears interest at a rate of 15% per annum, and has a maturity date of August 2, 2025. The note may be converted into common shares of the Company on the basis of a conversion price of \$0.05 per share. The note and the conversion terms are subject to approval by the TSX Venture Exchange.